Compass Therapeutics annual depreciation and amortization
2019
2020
2021
2022
2023
2024
2025
Compass Therapeutics Depreciation & Amortization Growth & History (CMPX)
Compass Therapeutics's depreciation and amortization was $276,000 for fiscal 2025.
View full Compass Therapeutics company overviewCompass Therapeutics annual depreciation and amortization history
| Fiscal year | Period ended | Depreciation and amortization | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $276,000 | −$313,000 | −53.14% |
| 2024 | 2024-12-31 | $589,000 | −$110,000 | −15.74% |
| 2023 | 2023-12-31 | $699,000 | −$83,000 | −10.61% |
| 2022 | 2022-12-31 | $782,000 | $182,000 | +30.33% |
| 2021 | 2021-12-31 | $600,000 | −$1.8M | −75.00% |
| 2020 · Dec 31 | 2020-12-31 | $2.4M | $300,000 | +14.29% |
| 2019 · Dec 31 | 2019-12-31 | $2.1M | — | — |
Compass Therapeutics quarterly depreciation and amortization
Q1.20
Q2.20
Q4.20
Q1.21
Q2.21
Q1.21
Q2.21
Q2.21
Q3.21
Q1.22
Q2.22
Q3.22
Q1.23
Q2.23
Q3.23
Q1.24
Q2.24
Q3.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Depreciation and amortization | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $21,000 | −$79,000 | −79.00% |
| Q1 2026 | 2026-03-31 | $15,000 | −$125,000 | −89.29% |
| Q4 2025 | 2025-12-31 | $370,000 | — | — |
| Q3 2025 | 2025-09-30 | $19,000 | −$124,000 | −86.71% |
| Q2 2025 | 2025-06-30 | $100,000 | −$52,000 | −34.21% |
| Q1 2025 | 2025-03-31 | $140,000 | −$14,000 | −9.09% |
| Q3 2024 | 2024-09-30 | $143,000 | −$21,000 | −12.80% |
| Q2 2024 | 2024-06-30 | $152,000 | −$28,000 | −15.56% |
| Q1 2024 | 2024-03-31 | $154,000 | −$40,000 | −20.62% |
| Q3 2023 | 2023-09-30 | $164,000 | −$38,000 | −18.81% |
| Q2 2023 | 2023-06-30 | $180,000 | −$40,000 | −18.18% |
| Q1 2023 | 2023-03-31 | $194,000 | $29,000 | +17.58% |
| Q3 2022 | 2022-09-30 | $202,000 | $64,000 | +46.38% |
| Q2 2022 | 2022-06-30 | $220,000 | — | — |
| Q1 2022 | 2022-03-31 | $165,000 | −$35,000 | −17.50% |
| Q3 2021 | 2021-09-30 | $138,000 | −$262,000 | −65.50% |
| Q2 2021 · Jun 30 | 2021-06-30 | $0 | −$400,000 | — |
| Q2 2021 · Jun 20 | 2021-06-20 | $147,000 | −$253,000 | −63.25% |
| Q1 2021 · Mar 31 | 2021-03-31 | $200,000 | −$300,000 | −60.00% |
| Q2 2021 · Sep 30 | 2020-09-30 | $400,000 | −$100,000 | −20.00% |
| Q1 2021 · Jun 30 | 2020-06-30 | $400,000 | −$100,000 | −20.00% |
| Q4 2020 | 2020-03-31 | $500,000 | — | — |
| Q2 2020 | 2019-09-30 | $500,000 | — | — |
| Q1 2020 | 2019-06-30 | $500,000 | — | — |
Compass Therapeutics depreciation and amortization trends
Over the last five fiscal years, Compass Therapeutics's depreciation and amortization decreased from $2.4M to $276,000, a change of −$2.1M. The latest reported quarter, Q2 2026, shows $21,000.
About the metric
What depreciation and amortization mean
Depreciation and amortization allocate the cost of tangible and intangible assets over their useful lives. These non-cash expenses reduce reported earnings and are commonly added back when calculating EBITDA and operating cash flow.
Calculation and source
Reported depreciation and amortization
TickerStat uses a combined depreciation and amortization value when reported. If a company reports the two components separately for an aligned period, they are added together without duplicating overlapping facts. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Compass Therapeutics source filings ↗